Evidence map›Paper›PMID 39188700›Full record

ArticleSmart medicine2024

Stevioside protects against acute kidney injury by inhibiting gasdermin D pathway.

Ruochen Qiao, Hui Wang, Dasheng Li, Yu Yang, Jiaxin Shu, Xiang Song, Xiaozhi Zhao, Li Lu

Abstract read
In one paragraph

Article in Smart medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. ALDH1L1 reverses CD8Journal of translational medicine · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ruochen QiaoInstitute of Translational Medicine the Affiliated Drum Tower Hospital of Nanjing University Medical School Nanjing Jiangsu China.
Hui WangHospital-Acquired Infection Control Department Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School Nanjing Jiangsu China.
Dasheng LiDepartment of Andrology Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School Nanjing Jiangsu China.
Yu YangDepartment of Andrology Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing Jiangsu China.
Jiaxin ShuDepartment of Andrology Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing Jiangsu China.
Xiang SongDepartment of Andrology Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing Jiangsu China.
Xiaozhi ZhaoDepartment of Andrology Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School Nanjing Jiangsu China.
Li LuDepartment of Andrology Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School Nanjing Jiangsu China.ORCID https://orcid.org/0000-0002-8127-5473

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies indicate a significant upregulation of gasdermin D (GSDMD) in acute kidney injury (AKI), a severe medical condition characterized by high morbidity and mortality globally. In this study, we identified and validated the therapeutic effects of small molecule inhibitors targeting the GSDMD pathway for AKI treatment. Using a drug screening assay, we evaluated thousands of small molecules from DrugBank against Lipopolysaccharide (LPS) and Nigericin-stimulated immortalized bone marrow-derived macrophages (iBMDMs) to discern GSDMD pathway activators. We simulated AKI in primary renal tubular epithelial cells using hydrogen peroxide (H

Indexed as

acute kidney injurygasdermin Dinflammationstevioside

Identifiers

PMID39188700
PMCPMC11235599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.